Drug intelligence / Profile preview

YGYFKY-1

Development stage: Preclinical
Lead developer: Silver Valley Pharmaceutical
Modality: Small Molecules

Overview

YGYFKY-1 is a small molecule drug candidate being developed by Silver Valley Pharmaceutical (Beijing Yingu Pharmaceutical) for the treatment of pain. Currently in the preclinical stage of development, the compound is part of the company's expanding pipeline in the analgesic therapeutic area. While the specific biological target and mechanism of action have not been publicly disclosed by the developer, YGYFKY-1 is being evaluated for its potential to address various pain indications. Silver Valley Pharmaceutical is a China-based pharmaceutical company focused on the research and development of innovative small molecule therapies across several disease areas, including respiratory and pain management.

Beyond the preview

Go deeper on YGYFKY-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YGYFKY-1.

Explore the full profile